Physician profile
Anna Patterson
NPI 1679076046
$1,366.27
in general payments reported to CMS, 2019-2025
21 companies · $713 in 2025
The $713 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.61 · 2024: $578 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $294.62 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $170.42 | 2025 | Repatha |
| Beta Bionics, INC. | $130.62 | 2024 | Ilet Bionic Pancreas |
| Novo Nordisk INC | $118.30 | 2025 | Ozempic, Rybelsus |
| Medtronic, INC. | $106.37 | 2024-2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $71.03 | 2024-2025 | |
| Corcept Therapeutics | $66.18 | 2024-2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $61.18 | 2025 | Yorvipath |
| Abbott Laboratories | $43.01 | 2025 | Freestyle Libre 3 |
| Abbvie INC. | $42.87 | 2021-2024 | |
| Genentech USA, INC. | $40.46 | 2021 | |
| Lilly USA, LLC | $37.81 | 2024-2025 | Mounjaro, Zepbound |
| Mannkind Corporation | $35.38 | 2024 | |
| Hologic Sales and Service, LLC | $21.45 | 2021 | |
| Boston Scientific Corporation | $20.70 | 2024 | Watchman Flx |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $19.36 | 2024 | Tymlos |
| Neurocrine Biosciences, INC. | $19.22 | 2024 | |
| Sequel Med Tech, LLC | $17.99 | 2025 | Twiist |
| Alexion Pharmaceuticals, INC. | $17.69 | 2025 | Strensiq |
| Sanofi-Aventis U.S. LLC | $17.64 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.97 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.